GSK, Alcon And Otsuka Obtain Japanese Approval Recommendations
This article was originally published in PharmAsia News
Executive Summary
Japan's First Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare granted approval recommendations July 30 to GlaxoSmithKline's anti-allergic agent Xyzal (levocetirizine), Alcon Japan's Nevanac (nepafenac) for pain and swelling after cataract surgery, and Otsuka Pharmaceutical's Samsca (tolvaptan) for hypervolemic hyponatremia